260 related articles for article (PubMed ID: 32031076)
1. Synergies of Targeting Angiogenesis and Immune Checkpoints in Cancer: From Mechanism to Clinical Applications.
Zhou S; Zhang H
Anticancer Agents Med Chem; 2020; 20(7):768-776. PubMed ID: 32031076
[TBL] [Abstract][Full Text] [Related]
2. Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers.
Shi Y; Li Y; Wu B; Zhong C; Lang Q; Liang Z; Zhang Y; Lv C; Han S; Yu Y; Xu F; Tian Y
Int Immunopharmacol; 2022 Sep; 110():108968. PubMed ID: 35764018
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B
Front Immunol; 2020; 11():1956. PubMed ID: 32983126
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.
Tartour E; Pere H; Maillere B; Terme M; Merillon N; Taieb J; Sandoval F; Quintin-Colonna F; Lacerda K; Karadimou A; Badoual C; Tedgui A; Fridman WH; Oudard S
Cancer Metastasis Rev; 2011 Mar; 30(1):83-95. PubMed ID: 21249423
[TBL] [Abstract][Full Text] [Related]
5. Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy.
Li S; Zhang Q; Hong Y
Technol Cancer Res Treat; 2020; 19():1533033820980116. PubMed ID: 33287656
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment.
Xue L; Gao X; Zhang H; Tang J; Wang Q; Li F; Li X; Yu X; Lu Z; Huang Y; Tang R; Yang W
BMC Cancer; 2021 Oct; 21(1):1134. PubMed ID: 34686154
[TBL] [Abstract][Full Text] [Related]
7. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
[TBL] [Abstract][Full Text] [Related]
8. Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.
Li SJ; Chen JX; Sun ZJ
Cancer Commun (Lond); 2021 Sep; 41(9):830-850. PubMed ID: 34137513
[TBL] [Abstract][Full Text] [Related]
9. Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors.
Zhu N; Weng S; Wang J; Chen J; Yu L; Fang X; Yuan Y
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3021-3036. PubMed ID: 31617075
[TBL] [Abstract][Full Text] [Related]
10. Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer.
Furukawa K; Nagano T; Tachihara M; Yamamoto M; Nishimura Y
Molecules; 2020 Aug; 25(17):. PubMed ID: 32859106
[TBL] [Abstract][Full Text] [Related]
11. The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies.
Melaiu O; Vanni G; Portarena I; Pistolese CA; Anemona L; Pomella S; Bei R; Buonomo OC; Roselli M; Mauriello A; Barillari G
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834641
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitor-Based Strategies for Synergistic Cancer Therapy.
He M; Yang T; Wang Y; Wang M; Chen X; Ding D; Zheng Y; Chen H
Adv Healthc Mater; 2021 May; 10(9):e2002104. PubMed ID: 33709564
[TBL] [Abstract][Full Text] [Related]
13. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
Georganaki M; van Hooren L; Dimberg A
Front Immunol; 2018; 9():3081. PubMed ID: 30627131
[TBL] [Abstract][Full Text] [Related]
14. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
15. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
17. The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer.
Leong A; Kim M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33217955
[TBL] [Abstract][Full Text] [Related]
18. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
19. Anti-angiogenesis: Opening a new window for immunotherapy.
Guo F; Cui J
Life Sci; 2020 Oct; 258():118163. PubMed ID: 32738363
[TBL] [Abstract][Full Text] [Related]
20. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies.
Atkins MB; Ascierto PA; Feltquate D; Gulley JL; Johnson DB; Khushalani NI; Sosman J; Yap TA; Kluger H; Sullivan RJ; Tawbi H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
